Clinical Trials in Australia / NCT07557602
Starting soon
Phase 1
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
NCT07557602 · tracked via the Priya Life Science Australia tracker
Condition(s) studied
EBV
Investigational drug(s) / intervention(s)
VXCO-102Placebo
VXCO-102: Sterile liquid for injection
Placebo: 0.9% sodium chloride (BP grade)
Study summary
This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Eligibility
Inclusion Criteria:
* Aged 18 to 25 years, inclusive
* Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment
Exclusion Criteria:
* Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation
* Likely or confirmed myocarditis or pericarditis
* Prior receipt of an investigational EBV vaccine
* Prior receipt of a licensed vaccine within 56 days prior to Day 1
* Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study.
* For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study
Note: Other inclusion and exclusion criteria apply.
Primary outcome measure(s)
- Number of Participants with Solicited Local and Systemic Reactions — 7 days after each product administration
- Number of Participants with Unsolicited Adverse Events — Up to 28 days after each product administration
- Number of Participants with Serious Adverse Events (SAEs) including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events of Special Interest (AESIs) — Day 1 to end of study (Day 357)
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Q-Pharm Pty Ltd/Nucleus Network Pty Ltd | Herston | Queensland | |
| Nucleus Network Pty Ltd | Melbourne | Victoria |
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07557602 on ClinicalTrials.gov ↗ ← All trials in Australia